SKSelda Sayin Kutlu

Selda Sayin Kutlu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Selda Sayin Kutlu has a total of 228 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Correction to: The Turkish Clinical Microbiology and Infectious Diseases Society (KLİMİK) Evidence-Based Guideline for the Diagnosis and Treatment of Brucellosis, 2023

    by Serap Şimşek-Yavuz, Selçuk Özger, Aysun Benli, Can Ateş, Mehtap Aydın, Gökhan Aygün, Alpay Azap, Özlem Kurt-Azap, Seniha Başaran, Neşe Demirtürk, et al.

    CORRECTION NOTE Two corrections have been made to the original version of this article, published on February 2, 2023: In Table 3, the information ‘DOX tablet 200 mg/day, single dose, oral +’ under the headings 1)Infective Endocarditis associated with Brucella spp. and 2) Neurobrucellosis has been corrected to: ‘DOX tablet 200 mg/day, 2 doses, oral +’. Corrected article: https://doi.org/10.36519/kd.2023.4576


  • Open Access

    Highlights on HIV Prevention and Antiretroviral Therapy from the Conference on Retroviruses and Opportunistic Infections (CROI) 2025 and Expectations from CROI 2026

    by Asuman İnAn, Selda Sayın-Kutlu, Meliha Çağla Sönmezer, Deniz Gökengin

    The Conference on Retroviruses and Opportunistic Infections (CROI) was held from March 9 to 12, 2025, in San Francisco, California, United States (US). The rapidly evolving field of HIV infection was reflected in data presented from cutting-edge scientific research at the conference. This review highlights data presented on two prominent topics during the meeting: HIV prevention and antiretroviral therapy (ART), with the aim of summarizing new data for the reader. The review also outlines the authors’ expectations for CROI 2026, which will be held from February 22 to 25, 2026, in Denver, Colorado, US. Keywords: HIV prevention, CROI, antiretroviral therapy, long-acting antiretrovirals

  • Causes of death in people living with human immunodeficiency virus in Türkiye: a multicentre retrospective study

    by Selda Sayın Kutlu, Ezgi Gülten, Adalet Altunsoy, Arzu Nazlı, Lütfiye Nilsun Altunal, Nuriye Taşdelen Fışgın, Dilek Yağcı Çağlayık, Halime Araz, Burcu Açıkalın Arıkan, Arda Kaya, et al.

    Purpose Effective antiretroviral therapy has significantly reduced mortality rates among people living with HIV (PWH) and has altered the distribution of causes of death. We aimed to investigate trends in causes of death among PWH over time. Methods We investigated all reported deaths in the Turkish Clinical Microbiology and Infectious Diseases Society HIV Cohort. Causes of death were categorized and analyzed across four time periods: 1997–2006, 2007–2014, 2015–2019, and 2020–2023. Factors associated with HIV/AIDS-related causes of death were compared to other causes of death. Results A total of 9,334 PWH were followed, of which 414 deaths (4.4%) occurred, including 44 (11.6%) among individuals assigned female at birth. The most common causes of death were AIDS-related illnesses (57.7%), non-AIDS-related cancers (11.1%), and cardiovascular diseases (9.9%). Among causes of death, the rate of AIDS-related diseases has declined over the years (p<0.001). Rates of non-AIDS-related cancers (p=0.013) and non-AIDS-related infections (p=0.008) have increased, and deaths due to comorbid conditions such as cardiovascular diseases have remained stable (p=0.193). In multivariate analysis, AIDS-related deaths were significantly associated with an increased risk in individuals who had an AIDS-defining illness at baseline. The rate of AIDS-related deaths declined in later periods compared to 1997–2006. AIDS-related deaths decreased with older age at HIV diagnosis. The rate of AIDS-related deaths was less frequent among men who have sex with men, smokers, and ex-smokers, individuals on antiretroviral therapy, those with higher CD4 counts, and individuals with comorbid diseases. Conclusions Among all deaths, AIDS-related deaths have declined. In contrast, the proportion of deaths attributed to non-AIDS-related cancers has increased, and the mortality rate from cardiovascular disease has remained unchanged over the years. Therefore, it is crucial to implement interventions that address comorbid conditions, particularly by enhancing the management of cardiovascular disease and cancer.

  • Open Access

    Asked the Expert: Current Perspectives on Community-Acquired and Healthcare-Associated Infections

    by Gulsah Tuncer, Ceyda Geyiktepe-Guclu, Gule Cinar, Hasan Selcuk Ozger, Selda Sayin-Kutlu, Gokhan Aygun, Alpay Azap, Serap Simsek-Yavuz

    The KLİMİK Association led the development of the KLİMİK Mobile application and made it available to association members on November 3, 2023. The app’s “Ask the Expert” module enables healthcare professionals to share their current questions in Clinical Microbiology and Infectious Diseases directly with specialist physicians. Users posed approximately 200 questions through the module between November 2023 and May 2025, and pre-selected experts answered all of them. This report compiles expert responses to 37 questions under “Community-Acquired Infections” and “Healthcare-Associated Infections,” along with the supporting sources. These findings highlight the practical needs of clinicians and support the translation of current evidence-based approaches into the field.

  • Open Access

    Demographical and Clinical Characteristics, Risk Factors, and Prognosis of Adult Patients with Herpes Zoster in Türkiye: A Retrospective, Multi-Center Study (VARICOMP-Adult Study)

    by Esin Senol, Alpay Azap, Selda Sayin Kutlu, Murat Kutlu, Ayse Erbay, Pelin Kocyigit, Emine Colgecen, Ozlem Ozbagcivan, Nilsel Ilter, Funda Yetkin, et al.

    Introduction: Over the past few decades, the rising incidence of herpes zoster (HZ) rates appears to have been a global phenomenon. In Türkiye, there is a lack of comprehensive studies addressing the HZ burden of disease, risk factors, and clinical characteristics. The aim of the VARICOMP-Adult study was to evaluate the clinical and demographic findings of adult patients with HZ. Patients and Methods: We enrolled the medical records of 1955 patients, 1010 females and 945 males, aged between 18 and 97 years between 2009 and 2014. Results: The presence of underlying conditions was present in 35.5% of patients and 345 patients (17.6%) had immunosuppression; 18.0% of patients required hospitalization. The mean age, the presence of underlying conditions, and immunosuppression in hospitalized cases with HZ were higher than those in outpatients. Logistic regression analysis revealed the following risk factors for hospitalization: age, immunosuppression, hypertension, hematological disorders, transplantation, COPD, and the presence of HZ opthalmicus or disseminated disease. We observed seven HZ cases with mortality aged between 58 and 80 years, and all cases had an underlying condition; 9.9% of the entire population reported postherpetic neuralgia (PHN), and age and no previous antiviral medications were the risk factors for PHN. Conclusions: This is the largest nationwide study of adult patients with HZ. Effective healthcare interventions such as antiviral therapy and immunization could prove beneficial in combating disease and treating HZ complications, especially in the high-risk population and individuals of older ages.


  • Open Access

    Evaluation of Cardiac Findings in People With Human Immunodeficiency Virus

    by Sevgi Özan Köse, Yalın Tolga Yaylalı, Yiğit Davutoğlu, Yiğit, Gürsel Şen, İbrahim Oğuz, Selda Sayın Kutlu

    The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.

  • Open Access

    A Systematic Review and Analysis of Brucella Endocarditis Cases

    by Seniha Başaran, Serap Şimşek-Yavuz, Mukime Elif Sarıcaoğlu, Mehtap Aydın, Gökhan Aygün, Alpay Azap, Özlem Azap, Aysun Benli, Neşe Demirtürk, Önder Ergönül, et al.

    Endocarditis is the most common cause of death from brucellosis. The information used to guide the management of cases with Brucella endocarditis has relied on case reports/series. Risk factors related to death and other adverse outcomes in patients with Brucella endocarditis were identified by an individual-patient data analysis of all reported Brucella endocarditis cases in the literature. The keywords “Bruce” and “endocard” were used to search articles published until July 2022 on PubMed and ULAKBIM databases. Case reports/series containing patients with endocarditis caused by Brucella spp., aged ≥17 years, and with data on antimicrobial or surgical treatment were included in the study. Epidemiological, clinical, laboratory, and treatment characteristics and outcomes of 273 cases from 86 eligible articles were recorded. It was found that male gender, a Wright serum tube agglutination (STA) titer of ≥1/1280 on admission, development of heart failure due to endocarditis were independent risk factors that increase mortality, while the usage of aminoglycoside and cardiac surgical intervention for endocarditis were factors reducing mortality. Including streptomycin or gentamicin in the treatment regimen may benefit patients with Brucella endocarditis. Valve surgery could be life-saving in patients with Brucella endocarditis. An STA titer of ≥1/1280, which probably reflects long-term and advanced disease, may be used as a marker for increased mortality. However, additional and more reliable studies are needed to define the most appropriate management approach in diagnosing and treating cases with Brucella endocarditis due to the low quality of the current evidence.


  • Open Access

    Visceral Leishmaniasis in A Patient Diagnosed with HIV/AIDS: The First Case in Turkey

    by Firuze Soyak, Suna Seçil Öztürk-Deniz, Zeliha Karazeybek, Mehmet Pekgüzel, Nilay Sen-Türk, Selda Sayın-Kutlu, Murat Kutlu

    Visceral leishmaniasis (VL) is an opportunistic infectious disease in people living with HIV. We report VL’s diagnosis and treatment process in a patient admitted to the hospital due to high fever during the first week of antiretroviral therapy. Leishmania indirect fluorescent antibody test titers were positive, and amastigotes were observed in the biopsy specimen. The patient’s condition improved following liposomal amphotericin B (LA-B) treatment. VL is endemic in Türkiye, and there is also an increase in HIV-positive cases. VL should be included in the differential diagnosis in HIV-positive cases alongside other opportunistic infections.

  • Open Access

    The Turkish Clinical Microbiology and Infectious Diseases Society (KLİMİK) Evidence-Based Guideline for the Diagnosis and Treatment of Brucellosis, 2023

    by Serap Simsek-Yavuz, Selcuk Ozger, Aysun Benli, Can Ates, Mehtap Aydin, Gokhan Aygun, Alpay Azap, Seniha Basaran, Nese Demirturk, Onder Ergonul, et al.

    Although brucellosis is very common in the world and Türkiye, there are no evidence-based guidelines to guide the diagnosis and treatment of the disease. This guide has been prepared by the Turkish Society of Clinical Microbiology and Infectious Diseases to provide evidence-based recommendations to physicians from different specialties interested in the diagnosis and treatment of brucellosis. The recommendations of the Clinical Practice Guide Development Guide of the Infectious Diseases Society of America (IDSA) were taken as the basis for preparing this guide. The guideline preparation group determined 20 questions considered to be important in the diagnosis and treatment of brucellosis, and the publications that could answer these questions prepared in PICO (Population/Patient [P], Intervention [I], Comparison [C], Outcome [O]) format, were searched in ULAKBİM Tr Dizin, PubMed, Cochrane databases without date restrictions. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) Working Group method was used to rank the evidence and determine the strength of the recommendations for each PICO question and for each individual outcome. Meta-analyses of comparative clinical studies were performed to answer the PICO questions. Individual participant data (IPD) meta-analyses with data obtained from case reports and case series were conducted in the absence of comparative clinical studies. It is planned to update the recommendations at regular intervals in line with the results of new studies.


  • Open Access

    Four Human Mpox Cases from Turkey

    by Emine Coskun, Firuze Soyak, Suna Secil Ozturk-Deniz, Murat Kutlu, Selda Sayın-Kutlu

    Human mpox (formerly monkeypox) disease has recently been reported in a number of European countries among individuals with no history of international travel or animal contact, causing global epidemic concerns. We describe the demographic, clinical characteristics, and laboratory data of four male patients with mpox disease, three of whom were human immunodeficiency virus (HIV)-positive, and one who was HIV-negative but had type 1 diabetes mellitus and a recent history of urological surgery. The HIV-negative patient attracted interest because he had no history of suspected sexual contact; however, he used shared bathrooms and towels at work, which could explain the potential transmission route. The remaining three male patients engaged in sexual activity with men recently. All four patients had prodromal symptoms such as short-term fever, myalgia, or fatigue, followed by a vesicular-pustular rash that began in the genital area, and two also had lesions on other parts of their bodies. Mpox is not generally considered in the differential diagnosis intitally because it is rare in Turkey; however, the diagnosis should be considered in patients with pustular umbilicated lesions and a history of risky sexual behavior. Keywords: mpox, outbreak, lesion, rash, HIV, infection